Thank you, Elrick. Ladies and gentlemen, a very good morning and good afternoon, and thank you for taking the time to join us on our quarter one FY27 earnings call.

The call is being chaired by our MD and CEO, Dr. Ashutosh Raghuvanshi.

With him, we have our Chief Financial Officer, Mr. Vivek Goyal.

From Agilus Diagnostics, we have the MD, Mr. Vijender Singh, and the Chief Financial Officer, Mr.

Aditya Tiwari. We will start with some opening comments on the quarter gone by by Dr.

Raghuvanshi, post which Mr. Vijender will take you through his thoughts on the diagnostics business for the quarter, and then we can open the floor for question and answers.

Over to Dr. Raghuvanshi.

Thank you, Anurag. Good morning, everyone, and thank you for taking time to join us on our Q1 financial year 27 earnings call today.

At the outset, I would like to welcome Mr. Vijender Singh, who has recently joined us as MD and CEO of Agilus Diagnostics.

I shall dive right into the quarterly results and share my thoughts on the business performance and way forward. Building on the momentum of previous year, we have made a positive start to the financial year, delivering a steady Q1 performance across both our hospitals and diagnostic businesses.

We reported consolidated revenue of INR 2,545 crore, a growth of 17.5% over Q1 of financial year 26. Notably, our hospital business revenues have grown by 19% to INR 2,187 crore, while Q1 financial year 27 diagnostic business gross revenue has grown up by 10.2% to INR 407 crore versus the previous corresponding quarter.

Our consolidated operating EBITDA pre-ESOP expenses increased by 15.8% to INR 568 crore, delivering a margin of 22.3% versus 22.6% in Q1 of financial year 26. The hospital business reported an operating EBITDA of INR 471 crore, which translates into a margin of 21.5% compared to 22.1% in Q1 of financial year 26.

Performance of the quarter also includes recent acquisitions, primarily related to the new hospital acquisitions in Punjab and Bengaluru, and the leased facility in Delhi NCR. Excluding the impact of these facilities on a like-to-like basis, operating EBITDA margin for the quarter was similar to Q1 of financial year 26 at 22%.

The operating EBITDA margin of the diagnostic business for the quarter improved to 23.9% from 23% in quarter one of financial year 26. Our consolidated reported profit after tax before exceptional items for the quarter increased by approximately 4% to INR 263 crore.

On the balance sheet front, the company's net debt stands at INR 2,233 crore with a net debt-to-EBITDA ratio of 1.01 as of June 30th, 2026, as against 0.92x on June 30th, 2025. The increase in net debt compared to INR 1,869 crore as on 30th June, '25 was primarily due to the acquisitions done last year.

A bit of flavor on the hospital business: our hospital occupancy in Q1 of financial year 27 remains steady at 69% compared to the corresponding period last year. However, the number of occupied beds increased by approximately 17% to 3,418 beds compared to 2,928 occupied beds in Q1 of financial year 26.

After factoring in our recent acquisitions, the hospital business recorded an increase in ARPOB of 2.6%, reaching INR 2.71 crore per annum. Our key specialties, such as renal sciences, neurosciences, and orthopedics, witnessed year-on-year revenue growth of 28%, 27%, and 23%, respectively.

In 14 of our facilities, we have reported operating EBITDA above 20% during the first quarter of financial year 27. These 14 facilities together contributed over 70% to the hospital revenues.

In comparison to financial year 26, we had 13 of our facilities operating EBITDA margin above 20%. Several of our key hospitals, such as Jaipur, Noida, Faridabad, and Mulund, witnessed margin expansion compared to the corresponding quarter of previous year and the trailing quarter.

In addition, many of our key facilities, such as Mulund and Faridabad, registered revenue growth in excess of 20% compared to the corresponding previous period. Our bed expansion plans continue to progress well.

During the quarter, we added approximately 100 operational beds through brownfield expansion, primarily across our Noida, Amritsar, and Jalandhar facilities. We also recently entered into an O&M agreement for a 300-bedded greenfield multi-specialty hospital to be developed in Cuttack.

This marks Fortis Healthcare's entry into Odisha, further expanding our presence in growth markets. Revenue from international business grew 13.3% compared to Q1 of financial year 26 to reach INR 174 crore.

The contribution of international business revenue stood at approximately 8% in Q1 of financial year 27, on the similar lines as Q1 of financial year 26. We continue to invest in our medical infrastructure by expanding advanced robotic capabilities across our network, reinforcing our commitment to clinical excellence and technology during the quarter.

We installed Da Vinci Xi soft tissue robot at Faridabad, Fortis Escorts Heart Institute, Okhla, and ortho robot at Jalandhar and Faridabad. Our board has also approved installation of a proton facility at our flagship hospital in Gurgaon as well.

Coming to the diagnostic business, as part of our ongoing network expansion strategy, the total number of new customer touch points reached 4,493 as of June 30th, 2026. The preventive and specialized portfolio revenues in Agilus overall revenue grew 27% and 13%, respectively, in Q1 of financial year 27 compared to the corresponding previous period.

In addition, the diagnostic business continues to witness an improvement in its product and customer mix, supported by higher contribution from B2C segment. We expect the growth momentum in revenue and improvement in operating EBITDA margin to continue going forward.

With that, I would like to conclude my remarks. We believe both our hospital and diagnostic business are well positioned to sustain their growth momentum backed by a strong balance sheet.

We will continue to evaluate inorganic growth opportunities that are aligned with our cluster strategy and have potential to create meaningful synergies. With that, I would like to hand over the call to Vijender for his comments.

We are very excited for him to join us, and we welcome him once again to the company.

Thank you, Dr. Raghuvanshi, and good morning, everyone.

Thank you for joining us today. On behalf of Agilus Diagnostics, I extend a warm welcome to all of you to discuss our performance for the first quarter of FY27.

FY27 has been a steady start for Agilus. During the quarter, we continue to execute our strategic priorities while strengthening our business across both consumer and institutional segments, investing in advanced diagnostics and improving operational efficiencies.

While the market remains competitive, our focus continues to be on building a stronger, more resilient business that is well positioned for sustainable long-term growth. During the quarter, we reported gross revenue of INR 407 crore, reflecting a 10.2% year-on-year growth over Q1 last year.

Operating EBITDA grew to INR 97 crore, while operating EBITDA margins improved from 23.9% compared to 23.0% in the corresponding quarter last year. These results reflect not only healthy business momentum, but also the benefits of our continued focus on productivity, operating leverage, and a richer test mix.

Operationally, we processed approximately 10.5 million tests during the quarter and expanded our network through the gross additions of over 200 customer touch points. Further strengthening our reach across the country, we also saw continuous momentum in our consumer business, with the B2C-B2B revenue mix improving to 53:47 in Q1 FY27 from 51:49 in Q1 FY26.

We continue to see a favorable shift in our portfolio mix, with the contribution from preventive portfolio increasing to 14% in Q1 FY27 from 12% in Q1 FY26, while the specialized portfolio contribution improved to 35% from 34% over the same period. Higher realization per test and per patient reflect increasing adoption of specialized diagnostics and a favorable shift in our portfolio mix.

Innovation continues to be a key pillar of our growth strategy. During the quarter, we achieved an important milestone by successfully completing over 1,000 whole exome sequencing tests on our NovaSeq X platform at our global reference laboratory in Mumbai.

This milestone reflects the growing adoption of advanced genomic testing and reinforces our commitment to making precision diagnostics more accessible to clinicians and patients across India. Beyond genomics, we continue to invest in digital capabilities while supporting long-term sustainable growth.

Looking ahead, we remain optimistic about the opportunities before us. Rising health awareness, increasing demand for preventive healthcare, and growing adoption of specialized diagnostics continue to create a favorable environment for the industry.

With our expanding network of strong scientific capabilities and continued investments in innovation and technology, we believe Agilus is well positioned to sustain profitable growth and create long-term value for all our stakeholders. Thank you.

Thank you, Vijender. Ladies and gentlemen, we shall now open the floor for question and answers.

May I please request the moderator to begin?

Good morning, and thanks for the opportunity. A couple of questions on your ESOP: assuming that most of the ESOP were given to doctors, wanted to understand what was the criteria behind choosing the pool of doctors that you decided to incentivize with ESOP, whether it was a broad-based strategy on India or whether currently it was only for hospital in Delhi NCR, assuming the competition is expected to heat up.

Hi.

No, Tauseef, thank you for your question. The strategy and the philosophy of ESOP was the primary consideration, and there was a lot of deliberation, and we decided that ESOP should be not only a tool to sort of recognize people's contribution, but at the same time also be as a tool of how the organization functioned in the future and how it performed in the future.

Both the components were kept in mind as to how the scheme was designed. Broad-based scheme was designed across the network.

It is not only limited to Delhi NCR, but it is across our network in all the different zones.

Just a follow-up question again on ESOP: also was this a pre-planned move to build loyalty or did the company observe some uptick in poaching attempts from the competitors, especially in Delhi NCR?

See, as far as the poaching activity is concerned, that keeps on happening periodically. We are not overly concerned about that.

We believe that our brand attracts the best possible clinicians because we provide an environment with good clinical infrastructure and an environment to function clinically independently. With that, I think we are an attractive magnet for clinicians.

We are not overly concerned about that. The idea was that the doctors participate in the growth of the organization, and their interests and the company's interests are aligned.

Clinicians help in many, many ways for the performance to improve in terms of controlling of the consumption, for instance, other efficiency measures which are necessary to have a better profitability profile, all those things, they become partners. That was the philosophy.

It was not a reactionary approach. It was a very well thought, calibrated strategy which was planned over a period of about 1 1/2 years before we actually implemented.

That's helpful. What is the ESOP charge one should assume for FY27 and next two fiscals?

After a soft start to hospital business on the EBITDA margins front, can we expect at least 100 basis improvement in EBITDA margin at a consol level for FY27?

Yeah. As per your question about the charge, what charge is to be there, right, the charge will be there for next three year and so.

The charge will initially be higher because it depends on the vesting and then it will gradually come down. As regards the margin guidance, we still maintain the margin guidance because overall all these would also contribute to the better operating performance overall because of this initiative.

That's helpful. I'll get back in the queue.

Thanks for taking my question. Vivek sir, on the margin, just to be sure, the 25% margin by FY28 is obviously pre-ESOP.

Would that be a fair understanding?

At that time, of course, the ESOP was not approved, Neha,

but

as I said, that ESOP charge has now come, and there will be some adjustment in the cost also, and there will be some improvement in the operating performance also because of the ESOP. Ultimately, whatever initiative you take is to contribute to the operating performance.

I'm confident with all these things, with some cost reductions, some improvement in the efficiency and revenue, we will able to maintain the margin. Just on this point, like the earlier person was asking question about the doctor poaching, generally in the industry practice, whenever the doctor poaching happened, we end up increasing the cost.

We hope that that cost will be curtailed to a great extent. All these initiatives have some plus, some minus, but ultimately, it is beneficial.

That's why company and the board has decided to roll this ESOP out.

Yeah. Neha, if I may just add, our guidance and our target does not change because we have several brownfield facilities which are coming online now, and like the FMRI facility has just got ready, and the final approvals are come in place now.

We would see some upside of that. At the same time, our Manesar facility has been continuously improving, so that is also going to significantly change the numbers.

We are pretty confident that we are still on track.

Understood, sir. This is very helpful.

My second question is on Manesar and Greater Noida. I think both of these facilities, deeply I understand, but Manesar and Noida both below 10% margin, and that's one of the reasons you mentioned for the muted margins in this quarter.

How much time do you think we get to 20% margins in both these hospitals? Manesar, if you could give us some color on how much bed we operationalized, etc., to help us get comfort on that margin improvement.

Manesar, we have operationalized about 187 beds, and the rest of the facility is also ready. As and when the occupancy goes up, currently it is about 60% occupancy on the current installed beds, so as that occupancy increases, we should be able to open more beds, as we are just in the process of getting the final approval for the last two floors as well.

Civil work and other things are completed. The second thing which is happening in Manesar is our radiation oncology equipment is under installation.

By the month of November, that should be installed. Once that is commissioned, then this hospital will become a comprehensive oncology center.

The growth in this top line has been as per our expectations. The profitability has not been in line with what we had expected.

We expect that the dynamics of the hospital will dramatically change once we have the oncology setup commissioned by the end of this calendar year. On the other hand, Noida is also showing steady increase.

Month on month, we are seeing about 8% to 10% growth on the revenue side. It's more a question of occupancy.

As we acquire more clinical talent, which we have been doing, we should expect good occupancy here as well. Both these hospitals, by the year-end, certainly be in the mid-teens as far as EBITDA is concerned, if not higher.

This is very helpful, sir. Thank you so much.

Thank you for taking my question. The first one is again slightly getting a better sense on the hospital EBITDA margin.

I think for this year, our original guidance was around 150 to 200 bps margin expansion. That though will be ex-ESOP, right?

While FY28 we are reiterating 25% normalized margin or reported margin, but this year, that will be ex-ESOP. That's first clarification I wanted.

Secondly, how do we kind of achieve that 25% EBITDA margin? Can you explain in a bit more detail what are the cost levers or is it pure operating leverage?

What are some of the building blocks for that?

Yeah. Karan, earlier guidance which we have given, that obviously not included this ESOP cost because it was not rolled out by that time.

As Dr. told, it has taken a lot of deliberation at company management level and board level, and after that, this was rolled out.

That was not the part of that. Having said that, as I said earlier, we are still maintaining our guidance.

This quarter on quarter may not be that way like this quarter there is a dip if we consider ESOP cost. Overall, in period of time, we are quite hopeful there we'll be reaching to 25%.

As regards the levers are concerned, one is there are new units which earlier Neha has pointed out. These units in the ramp-up stage, and in the current EBITDA margin trajectory, these units have contributed negatively by 0.4% to the overall EBITDA margin.

I am expecting this should contribute maybe 1% positively. That itself is a big delta.

Then the new doctors which we have taken and new teams which we have added in almost all our hospital units, we are quite hopeful they will start doing good because it takes that time for doctors to settle. Thirdly, there is some charge relating to the legal cost in the current quarter because of the ongoing Delhi High Court hearing which you people are aware.

There were intense hearing which has happened last quarter as well as in this quarter, and that legal cost has also burdened the profitability if we compare with the quarter one of the last year. Lastly, and which is also a very important point, the provision for doubtful debt has greatly gone up for this quarter because of there is certain delay in getting collection from the government payer as well as from other TPA.

The team is working on that, and I think that this also will be plugging back. There is another lever is on the existing hospital where the occupancy is less, and we have seen some tremendous improvement in those hospitals, specifically in BG Road and Mulund, where BG Road particularly where the occupancy is low.

These are the main lever, I will say, for our EBITDA margin improvement and to reach to 25% level.

Got it. My second question is with respect to the expansion plan.

Can you just rehash, say, over the next three, four quarters, what are the beds we are expecting to operationalize, which all facilities?

Yeah. In the first quarter, we have operationalized 100 beds, and we are expecting to operationalize another 400 beds in the remaining three quarters of the company.

The major contribution will be from our flagship hospital of FMRI, where all the work has been completed. We have applied for occupancy certificate.

We may expect that at any time, maybe this month itself, and that will give us 200 more beds. Then there are other of expansion which are on target.

We are doing quite well in terms of our bed expansion plan.

Got it. Thanks.

Just one quick bookkeeping one: so this ESOP charge, what is the annual number we are expecting this year and next year?

Yeah. This charge is, depend upon the ESOP vesting and the period and the number of people whom the option is given.

Because it is applicable the ESOP was rolled out from 23rd April, this year this quarter, it is for less number of days. The rest of the quarter, if the number of employees remain the same, the charge will be somewhere around INR 40 crore per quarter.

INR 40 crore per quarter, and thereafter, it should fall down to around 30. In the third year, also, it should be around 25 crore per quarter.

Got it. Thanks.

Hi. Thank you for the opportunity.

Again, a quick clarification: that 25% margin guidance which you are maintaining, that is including ESOP cost, which you think will be offset by a number of factors earlier discussed. Is that the correct understanding?

Yes. We are inspiring to achieve 25% EBITDA margin after running the ESOP cost.

Okay. Thank you for that.

My question is on your growth expansion strategy. During the quarter, you announced you are entering the Odisha market.

Earlier, my understanding was you generally take cluster-based approach to expand into a particular market, which can be seen in your presence in Delhi NCR and Bengaluru, etc. Now, how do you select market, or how do you go about when you try to expand beyond your traditional markets?

Some bit of understanding on that will be helpful.

Yes. No, Damayanti, our strategy has not changed.

We remain focused on the existing clusters. If you would have noticed, the hospital in Odisha is only an O&M project.

We are not committing any capital to that market at the moment. However, it is important for us to continue to focus, as I said, on the existing clusters, and we are evaluating opportunities in the clusters where we are present, and we hope that we will be able to conclude certain opportunities here pretty soon in the clusters where we are present.

At the same time, we also recognize that we will have to consider growing to new markets, especially the ones which have huge future potential and are contiguous in nature, and which we primarily have not been there. This is more for a learning, and then, depending on how these institutions perform, in future, we have a option with the O&M partner to participate in the growth of that region.

Otherwise, we are still focused only on the clusters we are present: in Bengaluru, Delhi NCR, Punjab, Mumbai Metropolitan Region, and Calcutta. We remain focused on that.

Of course, we are managing hospitals in Hyderabad and Chennai as well. We will in future consider what positioning we want to take in those two cities.

We want to always grow only in clusters because there are a lot of synergies which come operating in a given market. We are looking forward to quite a few opportunities, and hopefully, we should be able to conclude some.

Sure. Also want to hear some updates on the O&M hospital which you undertook for Gleneagles.

Compared to when it came under your operation and now, what kind of performance improvement we have seen, if you can specify some metrics, etc.?

We can't speak specific for this hospital, but in general, there's a lot of improvement is there. As we have entered into this arrangement only last year, there is a lot of evolution.

There is a lot of recruitment of new doctors and new teams has taken over there, and we are seeing very huge improvement in the operating margin in these facilities. Having said that, we can't give any specific number here at

this point. Safe to assume you have broadly stabilized the operations there, as you mentioned, and then margins are moving in positive trajectory there?

Yes. Currently, Damayanti, we are managing only the five hospitals, and we are not managing the Mumbai hospital, which is a separately managed hospital.

In these hospitals, we have improved the existing facilities and the operations. However, it is still not, I would say, completely stabilized.

We have not got it to the Fortis standard. That will take some time.

Our expectation is that it should take at least two, three quarters or maybe around four quarters before we can say that these are fully stabilized.

That's helpful. My last question is, Dr.

Raghuvanshi, you have highlighted adding oncology to new units will be one of the key booster for margins, etc. If you can talk a bit among all the new units, etc., or in the earlier list also, where oncology is yet to be added, and yeah, I think that's my question, which units are still missing that part?

Sure. As I just mentioned in an earlier question is that Manesar, we are in the process of installing the equipment, so that would be ready by the end of this calendar year.

There are two units where the work is just starting on a dedicated block in the brownfield expansion in Faridabad and in Amritsar, as well sorry, three units: Amritsar and Jaipur. These three units will also become full cancer hospitals as well.

This is in the pipeline at the moment.

Okay. Thank you, and wishing you all the best.

Thank you so much.

Hi. Thank you for the opportunity.

It's very good to hear that you are bringing proton therapy to Delhi NCR region. I just wanted to understand capex and timelines for this.

It is under finalization, it will be in the range of INR 250 crore.

Okay. Understood.

Second question is on the O&M, any of your O&M which is performing really well and you have a call option in current plan?

Yeah. We don't have too many O&Ms at the moment, and there is no call option in any of the two or three hospitals which we are operating.

On the other hand, the Gleneagles assets is a different matter where we are in discussions with IHH to see how we can proceed.

Understood. Thank you so much.

Thank you, sir. Thank you for the opportunity.

Sir, my question is on the diagnostic business. We are reporting only 9%, 10% top line growth whereas industry is growing at 15%, and specially our growth was largely on the account of realization improvement, whereas industry has witnessed strong demand growth.

Can you provide some color on what are the challenges we are facing? Is this related to still rebranding or all?

Thank you. I think since it's been 10 days I joined the organization, and probably we will rework on our plans.

Our standing continues to maintain growth, anchoring operating leverage from profit point of view. Our guidance continue to be maintained double-digit profit margin.

Of course, we'll come back with some of our major plans. Yes, when you look at our data, I think we are in the right direction as far as B2C business is concerned, which is more sticky, more profitable, and also kind of helping us in building our infrastructure keeping in mind our B2C ratio is growing from 53% to at least 55% and 58% in next few times from now.

I think we are on track, and probably it's a great opportunity to be associated with Agilus because Agilus comes with lot more scientific legacy. We're going to leverage that.

Yes, we are on right track, that's what, as of now, I can say.

If I can just add a little bit. I could just add because Mr.

Vijender Singh has just come on board, and he, as you might be aware, that he carries a huge body of experience on building scale. We are very privileged to have him, and we do recognize that there has been a muted growth or rather kind of a stagnant period for some time, and that was variety of factors, including the brand change, etc.

Now those things are getting stabilized. As they're getting stabilized, we have about 10% growth seen in the last quarter, and a lot of it has come from volume growth as well.

This is definitely a sign of revival. We have done a little bit of kind of a transformation project where we have rationalized some of our lab network along with the customer touch points.

That journey now will be accelerated under the new leadership and new management. With that, we are very confident that we will be able to bring it to the similar level.

Region-wise, we have seen that after we have started some focused effort in Delhi NCR, our growth in this region has been pretty good, and we are going to replicate the same thing in other regions as well. You're right that the growth has been slower than the other industry players, but we are completely on the path that we would be able to achieve similar levels within, say, next few quarters.

Thank you, sir. Good to hear.

Sir, my next question is on the hospital segment on our specialty mix. We have seen the 200 basis point decline on onco business.

Is this related to chemo business, or are there any other factor also?

You're absolutely right. The chemo business is the one which has impacted this.

Some of our regions hospital, all the hospitals in Punjab, as well as Jaipur, have large number of ECHS beneficiaries. Some of our hospitals in NCR have large number of CGHS beneficiaries.

In all these categories, the chemo drug pricing mechanism which they have come up with 30% discount on MRP is the one which is causing this dip. As you would have seen that earlier on, we were growing in oncology about 23%, 24%, but now that has come down to only about 5%.

We still feel that oncology is going to be a big growth driver in terms of volumes, and we are focusing a lot on radiation, as well as building the expertise on the surgical side of oncology and providing comprehensive care. That would drive our growth in oncology in future.

Certainly, it is going to be in the range of 10%, 12% and not like 27% which used to be earlier.

Sir. Sir, my last one is on Gleneagles.

Can you give us the absolute management fees we have generated from Gleneagles this quarter? We have a 2%, 3% O&M contract with Gleneagles.

We are adhering to that agreement. As per that agreement, we are eligible for 3% fee on the revenue, and that we are getting completely.

How much did we booked for this quarter?

Around INR 6 crore.

Okay. Thank you so much.

Hi, sir. Thank you for the opportunity.

Sir, my first question with regards to your occupancy: so this quarter, we understand it was kind of flattish because of the beds what you added, but if I look at your 14 facilities, which is contributing to the bulk of EBITDA, that is already having an occupancy of close to 74%. Sir, how should we look at growth for these hospitals?

That is question number one. Second is, for this balance six hospital in the range of, say, 10% to 20% margin, there seems to be some occupancy room, but if I look at previously, the numbers what you shared in FY26, their occupancy has kind of slid down.

Sir, if you could help us understand on both these aspects.

Yeah. We are consistently operating at around 70% occupancy on the enhanced beds.

If you see this occupancy is after taking the consideration the new unit where some renovation work is going on, for example, in our Bangalore unit and the other units which we have taken. The occupancy is impacted because of that to some extent, but still, it is at 70% around 70% occupancy.

As regards the lever for ramping up the occupancy, one is this new unit, including Manesar, this Richmond Road facility, Greater Noida facility, there are a lot of scope, and we are seeing the occupancy is going up as we are strengthening these network with better clinical talent and better marketing efforts. There are some big units which are still there with lower occupancy.

Bangalore, BG Road is one of them. This is a big lever for us to improve the occupancy level.

I think all this lever will be good enough to ramp up the occupancy going forward by another 2% to 3% percentage point.

Got it. Sir, next one is on your bed expansion plan at FMRI.

I heard you out when you called out on your guidance and the levers for it, but in the 25% margin guidance what you're providing, sir, at FMRI, how are we thinking about margins to play out in the next one or two years?

FMRI is already operating at a very decent EBITDA margin, which is around this number, 25%, 26%. With the new bed coming in, we hope and expect on the larger base, it will be able to maintain that EBITDA margin, and there will be some improvement, rather, in this EBITDA margin.

Initially, it will be like a status quo type of EBITDA margin. Going forward, there will be improvement in the EBITDA margin because we have to add some talent, we have to add some new players, we have to set up that facility, but we are confident that there will not be any margin drop initially, but there will be improvement in the margin.

Got it, sir. Thank you, and all the best.

I'm getting back in the queue.

Thank you for taking my question. Sir, what is your capex guidance for this year, and also, in the past year, we have seen some acquisitions, inorganic moves.

Is that something which we can expect this year as well?

Saion, thank you for this question. Generally, we are expecting because we are in the growth phase and we have this 2,000 bed expansion plan, without taking any acquisitions into consideration, we will be consuming around 50% of our EBITDA for our growth, which is brownfield expansion which is going on, plus some of the initiatives like Dr.

Raghuvanshi has mentioned for enhancing our technical capabilities like proton and other therapies which we are planning to invest in, including robotic surgeries.

Sir, inorganic moves?

Inorganic, we are actively looking at it, and there are some deals which we are actively pursuing. Until those are completed, we can't speak much about those deals, we have to wait for getting further details.

We could expect them to be in your focus clusters only, right? Is that a fair assessment?

Yes,

absolutely right. The second one, I don't know, maybe you might have explained, I just wanted to understand on the ESOP side, what's the policy?

Is it largely to the doctors, and how many doctors or what percentage of doctors have been awarded this ESOP, and what has been the criteria here?

It is not only for the doctors, first of all. It is to doctors and some senior staff of the company.

Roughly, it is around 55% to 60% to doctor, and balance is to administrative staff, including corporate. I think the proportion may go up and down depending upon the need to provide this ESOP.

Right now, it is at this level.

I see. Okay.

I think you've mentioned about attrition. Is that an issue in the industry in general you've seen?

Is it increasing in particular geography where you've seen that as an issue, given all the expansion that's happening? Incrementally, as a trend, are you seeing more attrition in the hospital sector?

No,

not really any kind of pattern we can see. However, it is within the micromarkets, when a new hospital opens, then obviously, there will be some disturbance in that local geography.

That pattern we have seen. As a general in some region there is a lot of attrition happening, that is not the case.

It's just within small micromarkets, like, for example, in Noida, you are aware that a couple of new hospitals opened up, and that did create a little flutter across all the hospitals, actually, and there were some changes. I think it is at par with what happens in normal course of business.

We are not unduly concerned about it because the supply of the clinical talent has improved significantly. The younger generation has started coming out after the seats have been increased in medical colleges about 15 years back, all those people have started coming out, finishing their training.

Gradually over the next few years, you will see that this will not be that big a problem.

Okay. Thanks for that.

I'll join back. Thank you.

Hi. Yeah.

Just a quick follow-up, I think an earlier participant asked on the onco share going down. I heard that you maybe were impacted by the ECHS segment, but that is broadly flat if I look from year on year.

Any comment there? Yeah.

Within that segment, there are pluses and minuses both which have happened. A lot of diagnostic tests, investigations, procedure prices have gone up, whereas, at the same time, the prices of chemotherapy, etc., have gone down.

The net effect is not significant, but it has moved to other specialty revenues. That is why you will see the ECHS contribution remains same, but the oncology as a division, that growth has become muted because of that.

Also, our base has been increasing continuously, since the growth was very high for about 4, 5 years, the base has also become very large.

Okay. Got it.

Thank you.

Thank you.

Thank you, sir, for taking my questions. My question is regarding this revenue and this margin guidance for our this diagnostic business, and also can you throw some more light on this specialty and this preventive mix for the next two years?

Thank you.

Can you repeat the question? I could not hear properly.

Hello? Am I audible, sir?

Hello?

Yeah. Yeah.

Yeah.

Wanted to know this revenue and margin guidance for our diagnostic business, and also some additional insights on our this preventive as well as this specialty mix for the next two years. Hope my question is audible to you.

You are asking for revenue that margin for prediction for the diagnostic business, am I right?

Yes, you're correct. Yeah.

Diagnostic business, Dr. Ashutosh earlier mentioned, we have already achieved double-digit revenue growth.

With our focus approach and the new team on the ground, we are expecting revenue growth to be around 23%, 24% 12% to 13%, and EBITDA margin should be in the range of 24%, 25% for the current running time.

Yeah.

Thank you, ladies and gentlemen. If there are any further follow-up queries, questions, clarifications, please feel free to reach out to us.

We'll help you the best possible. Thank you once again, and have a good day.